Biotech Values

[DewDiligence]

EARS reverse-merges into—(private)—Trasir Therapeutics:

https://www.globenewswire.com/news-release/2021/06/03/2241209/0/en/Auris-Medical-Announces-Acquisition-of-RNA-Therapeutics-Company-and-Plans-for-Strategic-Repositioning.html

Auris Medical Holding Ltd…today announced the acquisition of privately held Trasir Therapeutics, Inc. (“Trasir”), based in Tampa, FL, a pioneer in extrahepatic oligonucleotide delivery. The transaction, which closed on June 1, 2021, is the starting point for a strategic repositioning under which the Company intends to focus on the development of RNA therapeutics while in the medium term aiming to spin off or divest its existing assets in neurotology, rhinology and allergology. [Good luck finding a buyer for EARS’ legacy assets!]

…the Board of Directors of Auris Medical Holding Ltd. intends to call an extraordinary general meeting of shareholders to propose to change its corporate name to Altamira Therapeutics Ltd. Upon approval of the proposed name change, the Company’s shares will start trading under the ticker symbol “CYTO”…

Everything EARS attempted (tinnitus, COVID-19, and more) ended in failure, so a reverse-merger is logical.